U.S. drug regulators approved Amylyx Pharmaceuticals Inc.’s new drug for amyotrophic lateral sclerosis, or ALS, giving patients a new option for slowing progression of the fatal disease.
The drug is the first that the Food and Drug Administration has approved for ALS, also known as Lou Gehrig’s disease, in five years and promises to extend the lives of patients by several months.
